At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,977 enrolled
Drug / intervention
Dutasteridedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and/or Efficacy of AVODART(Dutasteride) Administered in Korean BPH(Benign Prostatic Hyperplasia) Patients According to the Prescribing Information
In Brief
An observational study evaluating Dutasteride for Benign Prostatic Hyperplasia and Prostatic Hyperplasia. Completed, enrolled 3,977 participants across 1 site.
Detailed Summary
An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety and/or efficacy of AVODART administered in Korean BPH patients according to the prescribing information
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2004
Primary CompletionJul 2010
First PostedFeb 2011
TodayJul 2026
First PostedFeb 18, 2011
Enrollment StartDec 1, 2004
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 15.4 years ago
Interventions
Dutasteridedrug
Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.